Krystal Biotech, Inc. (KRYS)
355.66
-15.81
(-4.26%)
USD |
NASDAQ |
Sep 04, 14:19
Krystal Biotech Cash from Investing (Quarterly) : -161.58M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -161.58M |
| March 31, 2026 | -63.58M |
| December 31, 2025 | 11.16M |
| September 30, 2025 | -4.286M |
| June 30, 2025 | -10.52M |
| March 31, 2025 | -54.77M |
| December 31, 2024 | -83.78M |
| September 30, 2024 | -34.33M |
| June 30, 2024 | -19.35M |
| March 31, 2024 | -25.98M |
| December 31, 2023 | -10.16M |
| September 30, 2023 | 105.19M |
| June 30, 2023 | -15.96M |
| March 31, 2023 | 3.563M |
| December 31, 2022 | -5.208M |
| September 30, 2022 | -14.74M |
| June 30, 2022 | -38.22M |
| March 31, 2022 | -55.91M |
| December 31, 2021 | -126.54M |
| September 30, 2021 | -37.17M |
| June 30, 2021 | -62.32M |
| Date | Value |
|---|---|
| March 31, 2021 | -0.747M |
| December 31, 2020 | -6.217M |
| September 30, 2020 | -2.709M |
| June 30, 2020 | -0.95M |
| March 31, 2020 | -1.305M |
| December 31, 2019 | -0.545M |
| September 30, 2019 | -0.705M |
| June 30, 2019 | -1.236M |
| March 31, 2019 | -2.482M |
| December 31, 2018 | -3.767M |
| September 30, 2018 | -2.755M |
| June 30, 2018 | -3.801M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | -0.159M |
| September 30, 2017 | -0.012M |
| June 30, 2017 | -0.032M |
| March 31, 2017 | -0.007M |
| December 31, 2016 | -0.009M |
| September 30, 2016 | -0.001M |
| June 30, 2016 | -0.005M |
| March 31, 2016 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 0.00 |
| TG Therapeutics, Inc. | 1.03M |
| Cytokinetics, Inc. | -507.00M |
| ADMA Biologics, Inc. | -2.256M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 74.79M |
| Cash from Financing (Quarterly) | 15.05M |
| Free Cash Flow | 257.78M |
| Free Cash Flow Per Share (Quarterly) | 2.323 |
| Free Cash Flow to Equity (Quarterly) | 71.48M |
| Free Cash Flow to Firm (Quarterly) | 71.22M |
| Free Cash Flow Yield | 2.39% |